Article
Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 May 1997
Giantonio B J, Alpaugh R K, Schultz J, McAleer C, Newton D W, Shannon B, Guedez Y, Kotb M, Vitek L, Persson R, Gunnarsson P O, Kalland T, Dohlsten M, Persson B, Weiner L M
Abstract excerpt
PURPOSE: To establish the maximum-tolerated dose (MTD) and define the toxicities of a single-dose infusion of PNU-214565, a recombinant Escherichia coli-derived fusion protein of Staphylococcal enterotoxin A (SEA) and the Fab-fragment of the C242 monoclonal antibody in patients with advanced colorectal and pancreatic carcinomas. To investigate the capability of PNU-214565 to induce a superantigen (SAg) response...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.